Implementation of a simplified flow cytometric assays for minimal residual disease monitoring in childhood acute lymphoblastic leukemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4957|94|1|94-99

ISSN： 1552-4949

Source： Cytometry. Part B: Clinical Cytometry, Vol.94, Iss.1, 2018-01, pp. : 94-99

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000

By  

Cytometry. Part B: Clinical Cytometry, Vol. 94, Iss. 1, 2018-01 ,pp. : 100-111

John Wiley & Sons Inc

Access to resources Recommend Favorite

A novel flow cytometric assay for detection of residual disease in patients with B‐lymphoblastic leukemia/lymphoma post anti‐CD19 therapy

By  

Cytometry. Part B: Clinical Cytometry, Vol. 94, Iss. 1, 2018-01 ,pp. : 112-120

John Wiley & Sons Inc

Access to resources Recommend Favorite

Detection of minimal residual disease in B lymphoblastic leukemia using viSNE

By  

Cytometry. Part B: Clinical Cytometry, Vol. 88, Iss. 5, 2015-09 ,pp. : 294-304

John Wiley & Sons Inc

Access to resources Recommend Favorite

AIEOP‐BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia

By  

Cytometry. Part B: Clinical Cytometry, Vol. 94, Iss. 1, 2018-01 ,pp. : 82-93

John Wiley & Sons Inc

Access to resources Recommend Favorite

Monitoring Minimal Residual Disease in AML

By Stewart CC  

Cytotherapy, Vol. 1, Iss. 4, 1999-01 ,pp. : 341-341

Ashgate Publishing Ltd

Access to resources Recommend Favorite